Comparison · NCT00395291-sae
MK-0677 vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. MK-0677 vs Placebo: serious adverse events. Trial comparisons, record NCT00395291-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00395291-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.154 | 0.0615 | 0.335 | wilson | |
| Risk in group 2 | 0.115 | 0.04 | 0.29 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0385 | -0.159 | 0.235 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.33 | 0.331 | 5.38 | log | |
| Odds ratio, group 1 over group 2 | 1.39 | 0.279 | 6.95 | log | |
| Number needed to harm, for one more participant with a serious adverse event on MK-0677 than on Placebo | 26 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | MK-0677 | Subjects took 25mg of MK-0677 for at least 30 Days. | 4 | 26 | EG000 |
| Group 2 | Placebo | Subjects took Placebo for at least 30 days. | 3 | 26 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse Events were collect from the time the subject started the first intervention and ended two weeks from the last study visit.
Source ClinicalTrials.gov
Trial
- Title
- Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients
- NCT number
- NCT00395291
- Phases
- NA
- Conditions
- Chronic Kidney Disease, End Stage Renal Disease
- Interventions
- MK-0677, Placebo
- Lead sponsor
- University of Virginia
- Results first posted
- 2012-01-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00395291?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00395291-sae